Target PharmaSolutions has named Novartis as its first industry partner to provide multi-year support to the company’s TARGET-DERM registry.
TARGET-DERM is a global longitudinal observational study that evaluates adult and pediatric patients with immune-mediated inflammatory skin conditions (IMISCs).
The study will initially focus on patients with eczema and will expand to include other skin conditions, including hidradenitis suppurativa – painful bumps under the skin, alopecia areata – autoimmune-related hair loss, and vitiligo and will be led by an academic steering committee chaired by Emma Guttman-Yassky, The Sol and Clara Kest Professor of Dermatology and Immunology.
“We are very excited for Novartis to join as the first industry partner in TARGET-DERM,” said Meg Powell, chair of the board of Target PharmaSolutions.
“We have received strong interest from many stakeholders in the dermatology community regarding the need for high-quality, longitudinal, real-world data on patients with eczema and other inflammatory skin conditions related to immune response.
Real-world data gathered from TARGET-DERM will be a valuable resource for our collaborators as they work to better understand and to combat these complex skin diseases, and could have life-altering implications for the millions of people around the world who suffer from them.”
TARGET-DERM is the sixth disease category spearheaded by Target PharmaSolutions since 2015, whose ongoing real-world studies include nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC) and chronic hepatitis B (HBV).
